Skip to content

A real-world study on improving insomnia in the physical examination population

A real-world study on improving insomnia in the physical examination population

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500110955
Enrollment
Unknown
Registered
2025-10-23
Start date
2025-11-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insomnia

Interventions

Observational group:None

Sponsors

Peking University Shenzhen Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Age 18 or above, gender not limited. 2.Voluntarily participate in this study and sign a written informed consent form. 3.Have a routine health check-up at the physical examination center. 4.Insomnia: PSQI total score >=7 points. 5.Be able to operate the equipment correctly and complete the questionnaire. 6.Agree to complete at least 20 treatments (compliance rate >=70%).

Exclusion criteria

Exclusion criteria: 1.According to the researchers' judgment, his insomnia is mainly caused by uncontrolled severe anxiety disorders, depression and other mental illnesses, or by substance abuse (such as alcohol and drugs). 2.Those who have implanted cardiac pacemakers, Implantable Cardioverter defibrillators (ICDs), or other electronic implants in their bodies. 3.There is skin damage, infection, malignant tumor or acute inflammation at the treatment site. 4.People suffering from severe cardiovascular diseases (such as unstable angina pectoris, severe arrhythmia), cerebrovascular diseases, liver and kidney dysfunction, or uncontrolled epilepsy and other serious physical diseases. 5.Pain-related diseases with a clear diagnosis that require special medical intervention, such as pain related to malignant tumors, acute traumatic pain, and the active stage of rheumatic immune diseases, etc. 6.Pregnant or lactating women. 7.Currently participating in other clinical trials or having used other experimental treatments within the past month. 8.The researcher believes that there are any other circumstances that make one unsuitable to participate in this study. 9.During the 10-week intervention period, pay attention to contraception.

Design outcomes

Primary

MeasureTime frame
Achieved therapeutic response at 10 weeks;

Countries

China

Contacts

Public ContactYang Lin

Peking University Shenzhen Hospital

13510331506@139.com+86 755 83923333

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026